康臣药业：上半年收入15.69亿元 同比增23.7%

Core Insights - Kangchen Pharmaceutical announced a revenue of RMB 1.569 billion for the six months ending June 30, 2025, representing an increase of approximately 23.7% compared to the six months ending June 30, 2024 [1] - The company's profit attributable to equity shareholders for the same period is RMB 498 million, which is an increase of about 24.6% compared to the previous year [1] Financial Performance - Revenue for the six months ending June 30, 2025: RMB 1.569 billion, up 23.7% from the previous year [1] - Profit attributable to equity shareholders for the same period: RMB 498 million, up 24.6% from the previous year [1]